Novo Nordisk is taking aim at Eli Lilly with a new obesity drug deal. Meanwhile, a survey shows doctors’ perception of the ...

Spending growth for simple medications used to treat common health problems is outstripping spending growth for pricey medications used to treat complex and chronic conditions, according to a new ...

Hims & Hers has risen since November 2024, outperforming the S&P 500. Click here to see why HIMS stock is a Buy.

Grammy Award-winning singer Meghan Trainor, 31, is flaunting a slimmer figure these days, leaving fans shocked at her ...

Despite the current downward trend of NVO, it is a good stock to add to one's portfolio for long-term gains due to strong ...

LIZZO sent her fans into a frenzy as she stripped to a busty little black dress amid her dramatic weight loss. The About Damn Time hitmaker chose the figure hugging garment, paired with a low-cut ...

Also in today’s newsletter, Trump sanctions Chinese companies over Iran oil shipments, and Foxconn set to sign contract to ...

The FDA wants bulk production of copycat versions of popular weight-loss drugs to stop, but telehealth companies and compounding pharmacies ...

More consistent accumulation demonstrated in bloodstream over a one-week duration with once-daily DehydraTECH-tirzepatide oral capsules as compared to once-weekly injection of Zepbound®As previously a ...

Novo Nordisk rejoined the ABPI after a two-year suspension linked to promotional concerns. Audits confirmed compliance with ...